Biota Pharmaceuticals Inc. (NASDAQ:AVIR) – Stock analysts at FBR & Co lowered their FY2017 earnings estimates for shares of Biota Pharmaceuticals in a report issued on Monday. FBR & Co analyst C. James now anticipates that the firm will post earnings per share of ($0.92) for the year, down from their prior forecast of ($0.91). FBR & Co currently has a “Outperform” rating on the stock. FBR & Co also issued estimates for Biota Pharmaceuticals’ FY2018 earnings at ($0.88) EPS, FY2019 earnings at ($0.86) EPS and FY2020 earnings at ($0.49) EPS.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Biota Pharmaceuticals in a research report on Tuesday. Ladenburg Thalmann initiated coverage on shares of Biota Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating for the company. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $5.50.

Shares of Biota Pharmaceuticals (NASDAQ:AVIR) traded up 3.4500% during trading on Wednesday, reaching $1.6552. The company had a trading volume of 103,841 shares. Biota Pharmaceuticals has a 52 week low of $1.23 and a 52 week high of $2.31. The stock’s 50-day moving average price is $1.38 and its 200-day moving average price is $1.46. The company’s market capitalization is $63.96 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fy2017-earnings-estimate-for-biota-pharmaceuticals-inc-issued-by-fbr-co-avir.html

Biota Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Wednesday, September 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.25 by $0.43. Biota Pharmaceuticals had a negative net margin of 272.04% and a negative return on equity of 46.02%.

Several hedge funds have recently modified their holdings of AVIR. California Public Employees Retirement System bought a new stake in shares of Biota Pharmaceuticals during the second quarter worth $139,000. BlackRock Fund Advisors bought a new stake in shares of Biota Pharmaceuticals during the second quarter worth $143,000. Towerview LLC bought a new stake in shares of Biota Pharmaceuticals during the second quarter worth $224,000. Dimensional Fund Advisors LP bought a new stake in shares of Biota Pharmaceuticals during the second quarter worth $290,000. Finally, BVF Inc. IL bought a new stake in shares of Biota Pharmaceuticals during the second quarter worth $292,000. 34.53% of the stock is owned by institutional investors.

About Biota Pharmaceuticals

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.

5 Day Chart for NASDAQ:AVIR

Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.